News - Respiratory and Pulmonary, aclidinium


Popular Filters

Aclidinium and formoterol fixed dose combo for COPD filed in Europe by Almirall


Spain’s largest drugmaker Almirall has filed a Marketing Authorization Application to the European…

aclidiniumAlmirallEuropeformoterolPharmaceuticalRegulationRespiratory and Pulmonary

Forest Labs and Almirall opt to delay US filing for combo COPD drug


USA-based Forest Laboratories (NYSE: FRX) and Spain's largest drugmaker Almirall (ALM:MC) said late yesterday…

aclidiniumAlmirallForest LaboratoriesformoterolNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTudorza Pressair

Mixed results for Almirall and Forest's LAMA/LABA combo for COPD


Spain's largest drugmaker Almirall (ALM: MC) and US partner Forest Laboratories (NYSE: FRX) have announced…

aclidiniumAlmirallForest LaboratoriesformoterolPharmaceuticalResearchRespiratory and Pulmonary

Added benefit of Almirall's aclidinium bromide is not proven, says Germany's IQWiG


The drug aclidinium bromide, trade names Eklira, Bretaris from Spain's largest drugmaker Almirall (ALM:…

aclidiniumAlmirallBretaris GenuairEkliraEuropePharmaceuticalPricingRegulationRespiratory and Pulmonary

Almirall out-licenses aclidinium to Invida for Australia and New Zealand


Leading Spanish drugmaker Almirall (ALM: MC) has granted Singapore-based Invida, a member of the Italian…

aclidiniumAlmirallAsia-PacificInvidaLicensingMenariniPharmaceuticalRespiratory and Pulmonary

Almirall sets up first direct North America presence


Almirall (ALM: MC), Spain's largest pharmaceutical company, says it has set up a new affiliate in Canada…

aclidiniumAlmirallMarkets & MarketingNorth AmericaPharmaceuticalRespiratory and Pulmonary

Credit Suisse focus on new drugs for COPD


New data will be presented at the European Respiratory Society, due to take place in Vienna, Austria,…

aclidiniumAlmirallGlaxoSmithKlineNovartisPharmaceuticalQVA149ResearchRespiratory and PulmonaryTheravanceVecturaZephyr

Almirall's aclidinium approved in Europe for COPD maintenance treatment


Spain's leading drugmaker, Almirall (ALM: MC) says that the European Commission has granted marketing…

aclidiniumAlmirallBretaris GenuairEklira GenuairEuropeMenariniPharmaceuticalRegulationRespiratory and Pulmonary

US FDA delays approval of Almirall and Forest Laboratories' COPD drug


The US Food and Drug Administration has said it will require a three-month extension to complete its…

aclidiniumAlmirallEkliraEuropeForest LaboratoriesLicensingMenariniNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTudorza Pressair

FDA panels back Forest and Almirall COPD drug and Chelsea’s Northera for NOH


The US Food and Drug Administration’s Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted 12…

aclidiniumAlmirallBiotechnologyChelsea TherapeuticsEkliraForest LaboratoriesNeurologicalNorth AmericaNortheraPharmaceuticalRegulationRespiratory and PulmonaryTudorza Pressair

Newron updates on deal Meiji Seika Pharma deal; Almirall out-licenses in Korea


Italy’s Newron Pharmaceuticals (SIX: NWRN) yesterday said it has finalized a definitive license…

aclidiniumAlmirallAsia-PacificDaewoongLicensingMeiji Seika PharmaNeurologicalNewron PharmaPharmaceuticalRespiratory and Pulmonarysafinamide

Almirall starts Ph III COPD trial; collaborates with BioFocus; and posts sales and earnings downturn


There was a batch of news from Spain’s largest drugmaker Almirall (ALM. MC), starting with the announcement…

aclidiniumAlmirallFinancialForest LaboratoriesFormoterol Fumarate Inhalation PowderPharmaceuticalResearchRespiratory and Pulmonary

Back to top